Abstract
The anticancer agent irinotecan (CPT-11) is widely used in several cancer regimens. However, drug–drug interaction effects and considerable interindividual variability in the pharmacokinetics of CPT-11 and its metabolites have been observed, leading to side effects. To solve these problems and promote CPT-11 treatment, we established and validated a simple, rapid, and sensitive LC–MS/MS method for the simultaneous quantitative determination of CPT-11 and its main metabolites (SN-38, SN-38G, and APC). Protein precipitation with methanol was selected for sample preparation. All separations were performed on an Agilent ZORBAX Eclipse XDB-C18 column (2.1 × 50 mm, 3.5 μm) under isocratic elution with a mobile phase consisting of acetonitrile and 0.1% formic acid. The mass spectrometer was operated with multiple reaction monitoring in positive ion mode. The method was validated as linear over the concentration ranges 16.9–6760 ng mL−1 for CPT-11, 2.3–920 ng mL−1 for SN-38, 2.5–1000 ng mL−1 for SN-38G, and 1.25–250 ng mL−1 for APC. The intra- and interbatch precisions and accuracies of the validated method were within acceptable limits (<15%). This method was successfully applied to a pharmacokinetic study of CPT-11 and its main metabolites in rats.
Graphical Abstract
Similar content being viewed by others
References
Vanhoefer U, Harstrick A, Achterrath W, Cao S, Seeber S, Rustum YM (2001) J Clin Oncol 19:1501–1518
Newton KF, Newman W, Hill J (2012) Colorectal Dis 14:3–17
Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, Sparreboom A (2001) Clin Cancer Res 7:2182–2194
Sai K, Kaniwa N, Ozawa S, Sawada JI (2001) Drug Metab Dispos 29:1505–1513
Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, Karrison T, Janisch L, Ramírez J, Rudin CM, Vokes EE, Ratain MJ (2004) J Clin Oncol 22:1382–1388
Owens TS, Dodds H, Fricke K, Hanna SK, Crews KR (2003) J Chromatogr B 788:65–74
de Jong FA, Mathijssen RH, de Bruijn P, Loos WJ, Verweij J, Sparreboom A (2003) J Chromatogr B 795:383–388
Ramesh M, Ahlawat P, Srinivas NR (2010) Biomed Chromatogr 24:104–123
Bardin S, Guo W, Johnson JL, Khan S, Ahmad A, Duggan JX, Ayoub J, Ahmad I (2005) J Chromatogr A 1073:249–255
Zhang W, Dutschman GE, Li X, Ye M, Cheng YC (2009) J Chromatogr B 877:3038–3044
Marangon E, Posocco B, Mazzega E, Toffoli G (2015) PLoS One 10:e118194
Slatter JG, Schaaf LJ, Sams JP, Feenstra KL, Johnson MG, Bombardt PA, Cathcart KS, Verburg MT, Pearson LK, Compton LD, Miller LL, Baker DR, Peshek CV, Lord RS 3rd (2000) Drug Metab Dispos 28:423–433
D’Esposito F, Tattam BN, Ramzan I, Murray M (2008) J Chromatogr B 875:522–530
US Department of Health and Human Services, US Food and Drug Administration, Center for Drug Evaluation and Research, Center for Veterinary Medicine (2001) Guidance for industry: bioanalytical method evaluation. http://www.fda.gov/downloads/Drugs/Guidances/ucm070107.pdf. Accessed 15 Oct 2013
Yang X, Hu Z, Chan SY, Goh BC, Duan W, Chan E, Zhou S (2005) J Chromatogr B 821:221–228
Basu S, Zeng M, Yin T, Gao S, Hu M (2016) J Chromatogr B 1015–1016:34–41
Acknowledgements
This study was financially supported by the National Natural Science Foundation of China (grants 81403012 and 81473287).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that there are no conflicts of interest.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Wang, N., Zhu, C., Zhai, X. et al. Development of LC–MS/MS Method for Simultaneous Determination of Irinotecan and Its Main Metabolites in Rat Plasma, and Its Application in Pharmacokinetic Studies. Chromatographia 80, 77–85 (2017). https://doi.org/10.1007/s10337-016-3207-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10337-016-3207-9